The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MYGN | -62.63% | -44.22% | -11.01% | +59% |
| S&P | +16.9% | +95.99% | +14.39% | +1,066% |
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
The genetic-testing company announced an acquisition and lowered its guidance.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $213.10M | 0.8% |
| Gross Profit | $142.40M | 4.3% |
| Gross Margin | 66.82% | 2.3% |
| Market Cap | $489.46M | -77.9% |
| Market Cap / Employee | $0.18M | 0.0% |
| Employees | 2.7K | 0.0% |
| Net Income | -$330.50M | -800.5% |
| EBITDA | $1.80M | 118.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.40M | -19.5% |
| Accounts Receivable | $137.00M | 16.3% |
| Inventory | 28.7 | 10.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $86.20M | -33.7% |
| Short Term Debt | $68.40M | 414.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.85% | -31.2% |
| Return On Invested Capital | -14.41% | -0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.40M | -530.8% |
| Operating Free Cash Flow | -$13.60M | -623.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.41 | 1.71 | 1.16 | 0.69 | -76.16% |
| Price to Sales | 3.02 | 1.49 | 0.98 | 0.59 | -78.65% |
| Price to Tangible Book Value | 18.75 | 9.39 | 5.31 | 3.04 | -81.86% |
| Enterprise Value to EBITDA | -1013.18 | -473.44 | -60.45 | 317.43 | -236.12% |
| Return on Equity | -16.4% | -17.2% | -13.8% | -70.0% | 232.95% |
| Total Debt | $143.10M | $140.30M | $157.60M | $154.60M | 7.89% |
MYGN earnings call for the period ending September 30, 2021.
MYGN earnings call for the period ending June 30, 2021.
MYGN earnings call for the period ending December 31, 2020.
MYGN earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
